HOOK HOOKIPA Pharma Inc

Price (delayed)

$6.02

Market cap

$59.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5

Enterprise value

-$27.1M

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.

Highlights
The revenue has soared by 166% QoQ
HOOKIPA Pharma's gross profit has surged by 166% QoQ
The debt has declined by 7% since the previous quarter but it has increased by 6% year-on-year

Key stats

What are the main financial stats of HOOK
Market
Shares outstanding
9.9M
Market cap
$59.57M
Enterprise value
-$27.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
1.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.51
Earnings
Revenue
$53.55M
EBIT
-$47.16M
EBITDA
-$43.89M
Free cash flow
-$82.83M
Per share
EPS
-$5
Free cash flow per share
-$8.37
Book value per share
$10.56
Revenue per share
$5.41
TBVPS
$14.74
Balance sheet
Total assets
$145.87M
Total liabilities
$41.35M
Debt
$6.08M
Equity
$104.52M
Working capital
$103.2M
Liquidity
Debt to equity
0.06
Current ratio
4.5
Quick ratio
4.19
Net debt/EBITDA
1.97
Margins
EBITDA margin
-81.9%
Gross margin
100%
Net margin
-88.7%
Operating margin
-119.4%
Efficiency
Return on assets
-28.7%
Return on equity
-47.3%
Return on invested capital
-263.2%
Return on capital employed
-40.5%
Return on sales
-88.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOOK stock price

How has the HOOKIPA Pharma stock price performed over time
Intraday
-3.68%
1 week
-7.24%
1 month
840.63%
1 year
613.27%
YTD
643.21%
QTD
920.34%

Financial performance

How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$53.55M
Gross profit
$53.55M
Operating income
-$63.93M
Net income
-$47.52M
Gross margin
100%
Net margin
-88.7%
The revenue has soared by 166% QoQ
HOOKIPA Pharma's gross profit has surged by 166% QoQ
The net margin has surged by 79% year-on-year and by 78% since the previous quarter
The operating margin has surged by 75% since the previous quarter and by 75% year-on-year

Growth

What is HOOKIPA Pharma's growth rate over time

Valuation

What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.57
P/S
1.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.51
The EPS has grown by 45% YoY and by 42% from the previous quarter
The P/B is 59% below the 5-year quarterly average of 1.4 and 5% below the last 4 quarters average of 0.6
The company's equity rose by 25% YoY and by 16% QoQ
The revenue has soared by 166% QoQ
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 9.4 and 57% lower than the last 4 quarters average of 2.6

Efficiency

How efficient is HOOKIPA Pharma business performance
The ROS has soared by 79% YoY and by 78% from the previous quarter
The company's return on invested capital has surged by 54% QoQ but it fell by 8% YoY
HOOKIPA Pharma's return on equity has increased by 45% QoQ and by 23% YoY
The ROA is up by 40% from the previous quarter and by 29% YoY

Dividends

What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOOK.

Financial health

How did HOOKIPA Pharma financials performed over time
The total liabilities has declined by 48% year-on-year and by 42% since the previous quarter
HOOK's quick ratio is up by 44% YoY and by 29% from the previous quarter
The debt is 94% smaller than the equity
The company's equity rose by 25% YoY and by 16% QoQ
HOOKIPA Pharma's debt to equity has decreased by 14% QoQ and by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.